Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 120

1.

Downstream Effect of a Proton Treatment Center on an Academic Medical Center.

Remick JS, Bentzen SM, Simone CB 2nd, Nichols E, Suntharalingam M, Regine WF.

Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):756-764. doi: 10.1016/j.ijrobp.2019.03.016. Epub 2019 Mar 15.

PMID:
30885776
2.

Prophylactic Cranial Irradiation vs Observation in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Long-term Update of the NRG Oncology/RTOG 0214 Phase 3 Randomized Clinical Trial.

Sun A, Hu C, Wong SJ, Gore E, Videtic G, Dutta S, Suntharalingam M, Chen Y, Gaspar LE, Choy H.

JAMA Oncol. 2019 Mar 14. doi: 10.1001/jamaoncol.2018.7220. [Epub ahead of print]

PMID:
30869743
3.

Lymph Node Size Predicts for Asymptomatic Brain Metastases in Patients With Non-small-cell Lung Cancer at Diagnosis.

Rice SR, Molitoris JK, Vyfhuis MAL, Edelman MJ, Burrows WM, Feliciano J, Nichols EM, Suntharalingam M, Donahue J, Carr SR, Friedberg J, Badiyan S, Simone CB 2nd, Feigenberg SJ, Mohindra P.

Clin Lung Cancer. 2019 Jan;20(1):e107-e114. doi: 10.1016/j.cllc.2018.09.014. Epub 2018 Sep 24.

PMID:
30337268
4.

Questions About a Clinical Trial Evaluating the Addition of Cetuximab to Definitive Chemoradiation Therapy With Paclitaxel and Cisplatin for Patients With Esophageal Cancer-Reply.

Suntharalingam M, Winter K, Ilson D.

JAMA Oncol. 2018 Jun 1;4(6):888-889. doi: 10.1001/jamaoncol.2018.0242. No abstract available.

PMID:
29596545
5.

Implications of Pathologic Complete Response Beyond Mediastinal Nodal Clearance With High-Dose Neoadjuvant Chemoradiation Therapy in Locally Advanced, Non-Small Cell Lung Cancer.

Vyfhuis MAL, Burrows WM, Bhooshan N, Suntharalingam M, Donahue JM, Feliciano J, Badiyan S, Nichols EM, Edelman MJ, Carr SR, Friedberg J, Henry G, Stewart S, Sachdeva A, Pickering EM, Simone CB 2nd, Feigenberg SJ, Mohindra P.

Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):445-452. doi: 10.1016/j.ijrobp.2018.02.003. Epub 2018 Feb 13.

PMID:
29559292
6.

Corrigendum to "Clinical outcomes of black vs. non-black patients with locally advanced non-small cell lung cancer" [Lung Cancer 114, (December 2017) 44-49].

Vyfhuis MAL, Bhooshan N, Molitoris J, Bentzen SM, Feliciano J, Edelman M, Burrows WM, Nichols EM, Suntharalingam M, Donahue J, Nagib M, Carr SR, Friedberg J, Badiyan S, Simone CB 2nd, Feigenberg SJ, Mohindra P.

Lung Cancer. 2018 Feb;116:105. doi: 10.1016/j.lungcan.2017.12.011. Epub 2017 Dec 27. No abstract available.

PMID:
29289353
7.

Clinical outcomes of black vs. non-black patients with locally advanced non-small cell lung cancer.

Vyfhuis MAL, Bhooshan N, Molitoris J, Bentzen SM, Feliciano J, Edelman M, Burrows WM, Nichols EM, Suntharalingam M, Donahue J, Nagib M, Carr SR, Friedberg J, Badiyan S, Simone CB 2nd, Feigenberg SJ, Mohindra P.

Lung Cancer. 2017 Dec;114:44-49. doi: 10.1016/j.lungcan.2017.10.016. Epub 2017 Nov 2. Erratum in: Lung Cancer. 2017 Dec 27;:.

PMID:
29173764
8.

Oncological outcomes from trimodality therapy receiving definitive doses of neoadjuvant chemoradiation (≥60 Gy) and factors influencing consideration for surgery in stage III non-small cell lung cancer.

Vyfhuis MAL, Bhooshan N, Burrows WM, Turner M, Suntharalingam M, Donahue J, Nichols EM, Feliciano J, Bentzen SM, Badiyan S, Carr SR, Friedberg J, Simone CB 2nd, Edelman MJ, Feigenberg SJ, Mohindra P.

Adv Radiat Oncol. 2017 Jul 31;2(3):259-269. doi: 10.1016/j.adro.2017.07.009. eCollection 2017 Jul-Sep.

9.

Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial.

Suntharalingam M, Winter K, Ilson D, Dicker AP, Kachnic L, Konski A, Chakravarthy AB, Anker CJ, Thakrar H, Horiba N, Dubey A, Greenberger JS, Raben A, Giguere J, Roof K, Videtic G, Pollock J, Safran H, Crane CH.

JAMA Oncol. 2017 Nov 1;3(11):1520-1528. doi: 10.1001/jamaoncol.2017.1598. Erratum in: JAMA Oncol. 2017 Nov 1;3(11):1589.

10.

Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer.

Lin SH, Merrell KW, Shen J, Verma V, Correa AM, Wang L, Thall PF, Bhooshan N, James SE, Haddock MG, Suntharalingam M, Mehta MP, Liao Z, Cox JD, Komaki R, Mehran RJ, Chuong MD, Hallemeier CL.

Radiother Oncol. 2017 Jun;123(3):376-381. doi: 10.1016/j.radonc.2017.04.013. Epub 2017 Apr 25.

PMID:
28455153
11.

Establishing quality indicators for neck dissection: Correlating the number of lymph nodes with oncologic outcomes (NRG Oncology RTOG 9501 and RTOG 0234).

Divi V, Harris J, Harari PM, Cooper JS, McHugh J, Bell D, Sturgis EM, Cmelak AJ, Suntharalingam M, Raben D, Kim H, Spencer SA, Laramore GE, Trotti A, Foote RL, Schultz C, Thorstad WL, Zhang QE, Le QT, Holsinger FC.

Cancer. 2016 Nov 15;122(22):3464-3471. doi: 10.1002/cncr.30204. Epub 2016 Jul 15.

12.

Utility of the ACE Inhibitor Captopril in Mitigating Radiation-associated Pulmonary Toxicity in Lung Cancer: Results From NRG Oncology RTOG 0123.

Small W Jr, James JL, Moore TD, Fintel DJ, Lutz ST, Movsas B, Suntharalingam M, Garces YI, Ivker R, Moulder J, Pugh S, Berk LB.

Am J Clin Oncol. 2018 Apr;41(4):396-401. doi: 10.1097/COC.0000000000000289.

13.

Changes in neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios during chemoradiation predict for survival and pathologic complete response in trimodality esophageal cancer patients.

Hyder J, Boggs DH, Hanna A, Suntharalingam M, Chuong MD.

J Gastrointest Oncol. 2016 Apr;7(2):189-95. doi: 10.3978/j.issn.2078-6891.2015.080.

14.

Pre-Chemoradiotherapy FDG PET/CT cannot Identify Residual Metabolically-Active Volumes within Individual Esophageal Tumors.

Lu W, Tan S, Chen W, Kligerman S, Feigenberg SJ, Zhang H, Suntharalingam M, Kang M, D'Souza WD.

J Nucl Med Radiat Ther. 2015 May;6(3). pii: 226. Epub 2015 Apr 29.

15.

Role of the endogenous nitric oxide inhibitor asymmetric dimethylarginine (ADMA) and brain-derived neurotrophic factor (BDNF) in depression and behavioural changes: clinical and preclinical data in chronic kidney disease.

Kielstein H, Suntharalingam M, Perthel R, Song R, Schneider SM, Martens-Lobenhoffer J, Jäger K, Bode-Böger SM, Kielstein JT.

Nephrol Dial Transplant. 2015 Oct;30(10):1699-705. doi: 10.1093/ndt/gfv253. Epub 2015 Jul 13.

PMID:
26175142
16.

Primary Gross Tumor Volume is an Important Prognostic Factor in Locally Advanced Esophageal Cancer Patients Treated with Trimodality Therapy.

Boggs DH, Hanna A, Burrows W, Horiba N, Suntharalingam M.

J Gastrointest Cancer. 2015 Jun;46(2):131-7. doi: 10.1007/s12029-015-9699-y.

PMID:
25759174
17.

Long-term results of radiation therapy oncology group 9903: a randomized phase 3 trial to assess the effect of erythropoietin on local-regional control in anemic patients treated with radiation therapy for squamous cell carcinoma of the head and neck.

Shenouda G, Zhang Q, Ang KK, Machtay M, Parliament MB, Hershock D, Suntharalingam M, Lin A, Rotman M, Nabid A, Hong S, Shehata S, Cmelak AJ, Sultanem K, Le QT.

Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):907-15. doi: 10.1016/j.ijrobp.2014.12.018. Epub 2015 Feb 7.

18.

State-of-the-art molecular imaging in esophageal cancer management: implications for diagnosis, prognosis, and treatment.

Lin J, Kligerman S, Goel R, Sajedi P, Suntharalingam M, Chuong MD.

J Gastrointest Oncol. 2015 Feb;6(1):3-19. doi: 10.3978/j.issn.2078-6891.2014.062. Review.

19.

A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).

Zandberg DP, Rollins S, Goloubeva O, Morales RE, Tan M, Taylor R, Wolf JS, Schumaker LM, Cullen KJ, Zimrin A, Ord R, Lubek JE, Suntharalingam M, Papadimitriou JC, Mann D, Strome SE, Edelman MJ.

Cancer Immunol Immunother. 2015 Mar;64(3):367-79. doi: 10.1007/s00262-014-1640-x. Epub 2014 Dec 24.

20.

Oropharyngeal cancer as a driver of racial outcome disparities in squamous cell carcinoma of the head and neck: 10-year experience at the University of Maryland Greenebaum Cancer Center.

Zandberg DP, Liu S, Goloubeva O, Ord R, Strome SE, Suntharalingam M, Taylor R, Morales RE, Wolf JS, Zimrin A, Lubek JE, Schumaker LM, Cullen KJ.

Head Neck. 2016 Apr;38(4):564-72. doi: 10.1002/hed.23933. Epub 2015 Jun 30.

21.

Response assessment in locally advanced head and neck cancer based on RECIST and volume measurements using cone beam CT images.

Hou J, Guerrero M, Suntharalingam M, D'Souza WD.

Technol Cancer Res Treat. 2015 Feb;14(1):19-27. doi: 10.7785/tcrt.2012.500403. Epub 2014 Nov 16.

PMID:
25403431
22.

Analysis of pathological complete response rates with paclitaxel-based regimens in trimodality therapy for esophageal cancer.

Boggs DH, Tarabolous C, Morris CG, Hanna A, Burrows W, Horiba N, Suntharalingam M.

Dis Esophagus. 2015 Oct;28(7):619-25. doi: 10.1111/dote.12243. Epub 2014 May 26.

PMID:
24863682
23.

In response to What are the best management strategies for radiation-induced xerostomia?

Hutchinson CT, Strome SE, Suntharalingam M.

Laryngoscope. 2014 Sep;124(9):E397. doi: 10.1002/lary.24675. Epub 2014 Apr 29. No abstract available.

PMID:
24623594
24.

The Benefit of Chemotherapy in Esophageal Cancer Patients With Residual Disease After Trimodality Therapy.

Kim GJ, Koshy M, Hanlon AL, Horiba MN, Edelman MJ, Burrows WM, Battafarano RJ, Suntharalingam M.

Am J Clin Oncol. 2016 Apr;39(2):136-41. doi: 10.1097/COC.0000000000000036.

25.

Modeling pathologic response of esophageal cancer to chemoradiation therapy using spatial-temporal 18F-FDG PET features, clinical parameters, and demographics.

Zhang H, Tan S, Chen W, Kligerman S, Kim G, D'Souza WD, Suntharalingam M, Lu W.

Int J Radiat Oncol Biol Phys. 2014 Jan 1;88(1):195-203. doi: 10.1016/j.ijrobp.2013.09.037. Epub 2013 Nov 1.

26.

What are the best management strategies for radiation-induced xerostomia?

Hutchinson CT, Suntharalingam M, Strome SE.

Laryngoscope. 2014 Feb;124(2):359-60. doi: 10.1002/lary.24035. Epub 2013 Sep 19. Review. No abstract available.

PMID:
24105656
27.

Effect of chronic elevated asymmetric dimethylarginine (ADMA) levels on granulopoiesis.

Beutel G, Perthel R, Suntharalingam M, Bode-Böger SM, Martens-Lobenhoffer J, Kielstein JT, Kielstein H.

Ann Hematol. 2013 Apr;92(4):505-8. doi: 10.1007/s00277-012-1636-6. Epub 2012 Dec 6.

PMID:
23224243
28.

Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy.

Tan S, Kligerman S, Chen W, Lu M, Kim G, Feigenberg S, D'Souza WD, Suntharalingam M, Lu W.

Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1375-82. doi: 10.1016/j.ijrobp.2012.10.017. Epub 2012 Dec 6.

29.

Single-fraction radiotherapy versus multifraction radiotherapy for palliation of painful vertebral bone metastases-equivalent efficacy, less toxicity, more convenient: a subset analysis of Radiation Therapy Oncology Group trial 97-14.

Howell DD, James JL, Hartsell WF, Suntharalingam M, Machtay M, Suh JH, Demas WF, Sandler HM, Kachnic LA, Berk LB.

Cancer. 2013 Feb 15;119(4):888-96. doi: 10.1002/cncr.27616. Epub 2012 Nov 16.

30.

SU-D-BRB-04: FDG-PET Histogram Distances: Novel Predictors of Tumor Response to Chemoradiotherapy.

Tan S, Zhang H, Kligerman S, Chen W, Kim G, Feigenberg S, D'Souza W, Suntharalingam M, Lu W.

Med Phys. 2012 Jun;39(6Part3):3615. doi: 10.1118/1.4734676.

PMID:
28517413
31.

Radiation therapy oncology group protocol 02-29: a phase II trial of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection and consolidative therapy for locally advanced non-small cell carcinoma of the lung.

Suntharalingam M, Paulus R, Edelman MJ, Krasna M, Burrows W, Gore E, Wilson LD, Choy H.

Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):456-63. doi: 10.1016/j.ijrobp.2011.11.069. Epub 2012 Apr 28.

PMID:
22543206
32.

Induction of MAGE-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma.

Voskens CJ, Sewell D, Hertzano R, DeSanto J, Rollins S, Lee M, Taylor R, Wolf J, Suntharalingam M, Gastman B, Papadimitriou JC, Lu C, Tan M, Morales R, Cullen K, Celis E, Mann D, Strome SE.

Head Neck. 2012 Dec;34(12):1734-46. doi: 10.1002/hed.22004. Epub 2012 Jan 27.

33.

Asymmetric dimethylarginine may mediate increased heat pain threshold in experimental chronic kidney disease.

Kielstein JT, Suntharalingam M, Perthel R, Rong S, Martens-Lobenhoffer J, Jäger K, Bode-Böger SM, Nave H.

Nephrol Dial Transplant. 2012 Mar;27(3):899-902. doi: 10.1093/ndt/gfr629. Epub 2011 Nov 29.

PMID:
22131232
34.

Adjuvant radiation therapy for high-grade and/or locally advanced major salivary gland tumors.

Mahmood U, Koshy M, Goloubeva O, Suntharalingam M.

Arch Otolaryngol Head Neck Surg. 2011 Oct;137(10):1025-30. doi: 10.1001/archoto.2011.158.

PMID:
22006781
35.

Prevalence and correlates of symptoms and uncertainty in illness among head and neck cancer patients receiving definitive radiation with or without chemotherapy.

Haisfield-Wolfe ME, McGuire DB, Soeken K, Geiger-Brown J, De Forge B, Suntharalingam M.

Support Care Cancer. 2012 Aug;20(8):1885-93. doi: 10.1007/s00520-011-1291-9. Epub 2011 Oct 4.

PMID:
21964642
36.

Impact of early percutaneous endoscopic gastrostomy tube placement on nutritional status and hospitalization in patients with head and neck cancer receiving definitive chemoradiation therapy.

Rutter CE, Yovino S, Taylor R, Wolf J, Cullen KJ, Ord R, Athas M, Zimrin A, Strome S, Suntharalingam M.

Head Neck. 2011 Oct;33(10):1441-7. doi: 10.1002/hed.21624. Epub 2010 Dec 15.

PMID:
21928416
37.

Phase II study evaluating the addition of cetuximab to the concurrent delivery of weekly carboplatin, paclitaxel, and daily radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck.

Suntharalingam M, Kwok Y, Goloubeva O, Parekh A, Taylor R, Wolf J, Zimrin A, Strome S, Ord R, Cullen KJ.

Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1845-50. doi: 10.1016/j.ijrobp.2011.02.062. Epub 2011 May 19.

38.

Evaluation of the role of radiation therapy in the management of malignant thymoma.

Patel S, Macdonald OK, Nagda S, Bittner N, Suntharalingam M.

Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1797-801. doi: 10.1016/j.ijrobp.2011.03.010. Epub 2011 May 17.

PMID:
21596484
39.

Primary tumor volume is an important predictor of clinical outcomes among patients with locally advanced squamous cell cancer of the head and neck treated with definitive chemoradiotherapy.

Strongin A, Yovino S, Taylor R, Wolf J, Cullen K, Zimrin A, Strome S, Regine W, Suntharalingam M.

Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1823-30. doi: 10.1016/j.ijrobp.2010.10.053. Epub 2011 May 5.

PMID:
21549516
40.

Neoadjuvant paclitaxel poliglumex, cisplatin, and radiation for esophageal cancer: a phase 2 trial.

Dipetrillo T, Suntharalingam M, Ng T, Fontaine J, Horiba N, Oldenburg N, Perez K, Birnbaum A, Battafarano R, Burrows W, Safran H.

Am J Clin Oncol. 2012 Feb;35(1):64-7. doi: 10.1097/COC.0b013e318201a126.

PMID:
21297434
41.

Outcomes after trimodality therapy for esophageal cancer: the impact of histology on failure patterns.

Koshy M, Greenwald BD, Hausner P, Krasna MJ, Horiba N, Battafarano RJ, Burrows W, Suntharalingam M.

Am J Clin Oncol. 2011 Jun;34(3):259-64. doi: 10.1097/COC.0b013e3181e841ce.

PMID:
20686405
42.

Impact of neoadjuvant radiation on survival in stage III non-small-cell lung cancer.

Koshy M, Goloubeva O, Suntharalingam M.

Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1388-94. doi: 10.1016/j.ijrobp.2009.12.066. Epub 2010 Jun 3.

PMID:
20605359
43.

Pneumonectomy for lung cancer after preoperative concurrent chemotherapy and high-dose radiation.

Krasna MJ, Gamliel Z, Burrows WM, Sonett JR, Kwong KF, Edelman MJ, Hausner PF, Doyle LA, DeYoung C, Suntharalingam M.

Ann Thorac Surg. 2010 Jan;89(1):200-6; discussion 206. doi: 10.1016/j.athoracsur.2009.08.069.

PMID:
20103235
44.

Squamous cell carcinoma of the esophagus: treat with how many modalities?

Cheng S, Iannettoni M, Koshy M, Suntharalingam M, Urba S.

Semin Oncol. 2009 Dec;36(6):493-7. doi: 10.1053/j.seminoncol.2009.09.002. No abstract available.

PMID:
19995639
45.

Tomographic image via background subtraction using an x-ray projection image and a priori computed tomography.

Zhang J, Yi B, Lasio G, Suntharalingam M, Yu C.

Med Phys. 2009 Oct;36(10):4433-9.

46.

Optimal beam arrangement for stereotactic body radiation therapy delivery in lung tumors.

Lim DH, Yi BY, Mirmiran A, Dhople A, Suntharalingam M, D'Souza WD.

Acta Oncol. 2010;49(2):219-24. doi: 10.3109/02841860903302897.

PMID:
19888895
47.

Investigation of motion sickness and inertial stability on a moving couch for intra-fraction motion compensation.

D'Souza WD, Malinowski KT, Van Liew S, D'Souza G, Asbury K, McAvoy TJ, Suntharalingam M, Regine WF.

Acta Oncol. 2009;48(8):1198-203. doi: 10.3109/02841860903188668.

PMID:
19863229
48.

Clinical utility of postchemoradiation endoscopic brush cytology and biopsy in predicting residual esophageal adenocarcinoma.

Peng HQ, Halsey K, Sun CC, Manucha V, Nugent S, Rodgers WH, Suntharalingam M, Greenwald BD.

Cancer. 2009 Dec 25;117(6):463-72. doi: 10.1002/cncy.20051.

49.

Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients.

Settle K, Posner MR, Schumaker LM, Tan M, Suntharalingam M, Goloubeva O, Strome SE, Haddad RI, Patel SS, Cambell EV 3rd, Sarlis N, Lorch J, Cullen KJ.

Cancer Prev Res (Phila). 2009 Sep;2(9):776-81. doi: 10.1158/1940-6207.CAPR-09-0149. Epub 2009 Jul 29.

50.

Phase I trial of carboplatin/paclitaxel/bortezomib and concurrent radiotherapy followed by surgical resection in Stage III non-small cell lung cancer.

Edelman MJ, Burrows W, Krasna MJ, Bedor M, Smith R, Suntharalingam M.

Lung Cancer. 2010 Apr;68(1):84-8. doi: 10.1016/j.lungcan.2009.05.003. Epub 2009 Jun 21.

PMID:
19540615

Supplemental Content

Loading ...
Support Center